X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (572) 572
Publication (69) 69
Book Review (13) 13
Newsletter (13) 13
Book Chapter (7) 7
Book / eBook (6) 6
Conference Proceeding (2) 2
Newspaper Article (2) 2
Magazine Article (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (318) 318
humans (263) 263
animals (260) 260
male (236) 236
glutamate (189) 189
female (181) 181
glutamate decarboxylase (179) 179
neurosciences (142) 142
rats (134) 134
gaba (122) 122
glutamate decarboxylase - metabolism (109) 109
psychiatry (97) 97
research (91) 91
adult (89) 89
mice (89) 89
glutamate decarboxylase - immunology (84) 84
pharmacology & pharmacy (81) 81
brain (77) 77
middle aged (74) 74
anxiety (73) 73
medicine (67) 67
disease models, animal (65) 65
research article (64) 64
clinical neurology (62) 62
multidisciplinary sciences (59) 59
physiological aspects (59) 59
diabetes (58) 58
mental disorders (58) 58
gamma-aminobutyric acid - metabolism (57) 57
neurons (57) 57
rats, sprague-dawley (55) 55
health aspects (54) 54
analysis (53) 53
diabetes mellitus, type 1 - immunology (52) 52
glutamate decarboxylase - genetics (52) 52
rodents (52) 52
anxieties (49) 49
metabolism (49) 49
schizophrenia (48) 48
endocrinology & metabolism (47) 47
risk factors (47) 47
science (47) 47
nervous system (46) 46
γ-aminobutyric acid (45) 45
article (44) 44
insulin (44) 44
mental depression (44) 44
children (42) 42
parkinson's disease (42) 42
studies (42) 42
type 1 diabetes (42) 42
adolescent (41) 41
glutamic acid (41) 41
amino acids (40) 40
autoantibodies - blood (40) 40
enzymes (40) 40
expression (40) 40
dopamine (39) 39
depression (38) 38
proteins (38) 38
time factors (38) 38
care and treatment (37) 37
clinical trials (37) 37
genetic aspects (37) 37
autoimmunity (36) 36
child (36) 36
double-blind (36) 36
gene expression (36) 36
rats, wistar (36) 36
aged (35) 35
autoantibodies (35) 35
mellitus (35) 35
neurology (35) 35
gamma-aminobutyric-acid (34) 34
glutamic-acid decarboxylase (34) 34
pregnancy (34) 34
epilepsy (33) 33
treatment outcome (33) 33
drug therapy (32) 32
hippocampus (32) 32
mental health (32) 32
patients (32) 32
stress (30) 30
glutamate-decarboxylase (29) 29
brain - metabolism (28) 28
glutamic acid - metabolism (28) 28
mice, inbred c57bl (28) 28
biochemistry & molecular biology (27) 27
diabetes mellitus (27) 27
neurons - drug effects (27) 27
seizures (27) 27
basal ganglia (26) 26
gamma-aminobutyric acid (26) 26
immunology (26) 26
physiology (26) 26
prefrontal cortex (26) 26
biology (25) 25
dose-response relationship, drug (25) 25
review (25) 25
animal models (24) 24
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (592) 592
Russian (4) 4
Spanish (4) 4
French (2) 2
Turkish (2) 2
Chinese (1) 1
Japanese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 5, pp. 433 - 442
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2008, Volume 359, Issue 18, pp. 1909 - 1920
Journal Article
Journal Article
Diabetologia, ISSN 0012-186X, 7/2009, Volume 52, Issue 7, pp. 1363 - 1368
Journal Article
Journal of Diabetes and Its Complications, ISSN 1056-8727, 2005, Volume 19, Issue 4, pp. 238 - 246
Journal Article
Diabetologia, ISSN 0012-186X, 3/2011, Volume 54, Issue 3, pp. 634 - 640
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2012, Volume 7, Issue 1, p. e30561
Background: Loss of GABA-mediated pre-synaptic inhibition after spinal injury plays a key role in the progressive increase in spinal reflexes and the... 
CELLS | UPTAKE INHIBITOR | MULTIDISCIPLINARY SCIENCES | RIGIDITY | RATS | NEURONS | INTRATHECAL BACLOFEN | VECTORS | CORD-INJURY | DORSAL-HORN | TIAGABINE | Neuroprotective Agents - therapeutic use | Embryo, Mammalian | GABA Agonists - administration & dosage | Spine - metabolism | GABA Agonists - adverse effects | Anticonvulsants - administration & dosage | Male | Glutamate Decarboxylase - administration & dosage | GABA Agonists - therapeutic use | Muscle Spasticity - drug therapy | Muscle Spasticity - therapy | Anticonvulsants - adverse effects | Swine | Glutamate Decarboxylase - adverse effects | Swine, Miniature | Female | Neuroprotective Agents - adverse effects | Neuroprotective Agents - administration & dosage | Spine - pathology | Nipecotic Acids - administration & dosage | Injections, Spinal | Cells, Cultured | Nipecotic Acids - therapeutic use | Anticonvulsants - therapeutic use | Gene Expression Regulation - physiology | Rats | Glutamate Decarboxylase - genetics | Combined Modality Therapy | Rats, Sprague-Dawley | Animals | Nipecotic Acids - adverse effects | Muscle Spasticity - genetics | Genetic Therapy - methods | Anticonvulsants | Genes | Baclofen | GABA | Spasticity | Glutamate decarboxylase | Glutamate | Drugs | Neurosciences | Laboratories | Neurobiology | Segments | Tiagabine | γ-Aminobutyric acid | Ischemia | Rodents | Physiology | Reflexes | γ-Aminobutyric acid B receptors | Gene transfer | Neurons | Muscles | Injection | Bioavailability | Gene expression | Trauma | Side effects | Correlation analysis | Stem cells | Spinal cord injuries | Intubation | Anesthesiology
Journal Article
Expert Opinion on Biological Therapy, ISSN 1471-2598, 05/2010, Volume 10, Issue 5, pp. 787 - 799
Importance of the field: Type 1 diabetes is a common and very serious disease. There has been very active research going on for a long time aiming at... 
Diamyd | type 1 diabetes | GAD | GADA | immune intervention | prevention | Prevention | Immune intervention | Type 1 diabetes | MEDICINE, RESEARCH & EXPERIMENTAL | IMMUNE-RESPONSE | GLUTAMIC-ACID DECARBOXYLASE | BETA-CELL FUNCTION | PROTEIN PEPTIDE DIAPEP277 | DIABETES-MELLITUS | RECENT-ONSET | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | DOUBLE-BLIND | GENE-THERAPY | C-PEPTIDE | T-CELLS | Alum Compounds - therapeutic use | Recombinant Proteins - therapeutic use | Immunotherapy - methods | Humans | Middle Aged | Child, Preschool | Diabetes Mellitus, Type 1 - metabolism | Recombinant Proteins - adverse effects | Adjuvants, Immunologic - adverse effects | Young Adult | Insulin-Secreting Cells - metabolism | Glutamate Decarboxylase - adverse effects | Glutamate Decarboxylase - therapeutic use | Adult | Diabetes Mellitus, Type 1 - immunology | Glutamate Decarboxylase - immunology | Adjuvants, Immunologic - therapeutic use | Alum Compounds - adverse effects | Child | Insulin Secretion | Immune Tolerance | Treatment Outcome | Evidence-Based Medicine | Insulin-Secreting Cells - immunology | Diabetes Mellitus, Type 1 - drug therapy | Insulin - metabolism | Animals | Insulin-Secreting Cells - drug effects | Recombinant Proteins - immunology | Adolescent | Aged | Medical and Health Sciences | Medicin och hälsovetenskap | MEDICIN | MEDICINE
Journal Article
Immunotherapy, ISSN 1750-743X, 03/2011, Volume 3, Issue 3, pp. 323 - 332
Glutamic acid decarboxylase (GAD)-alum (Diamyd (R), Diamyd Medical, Stockholm, Sweden) is an adjuvant-formulated vaccine incorporating recombinant human GAD65,... 
LADA | autoimmune diabetes | β-cell | C-peptide | rhGAD65 | GAD-alum | GLUTAMIC-ACID DECARBOXYLASE | ANTI-CD3 MONOCLONAL-ANTIBODY | COSTIMULATION MODULATOR ABATACEPT | IMMUNOLOGY | BETA-CELL FUNCTION | PROTEIN PEPTIDE DIAPEP277 | PHASE-II TRIAL | beta-cell | RECENT-ONSET | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | STIFF-MAN SYNDROME | Recombinant Proteins - therapeutic use | Immunotherapy - methods | Humans | Vaccination | Th2 Cells - immunology | Diabetes Mellitus, Type 1 - therapy | Isoenzymes - immunology | T-Lymphocytes, Regulatory - immunology | Insulin-Secreting Cells - metabolism | Immune Tolerance - immunology | Glutamate Decarboxylase - adverse effects | Glutamate Decarboxylase - therapeutic use | Adult | Diabetes Mellitus, Type 1 - immunology | Glutamate Decarboxylase - immunology | Adjuvants, Immunologic - therapeutic use | Glutamate Decarboxylase - pharmacokinetics | Isoenzymes - therapeutic use | Immunomodulation | Isoenzymes - genetics | Vaccines - immunology | Aluminum Hydroxide - therapeutic use | Glutamate Decarboxylase - genetics | Clinical Trials as Topic | Recombinant Proteins - genetics | Insulin-Secreting Cells - immunology | Autoantibodies - immunology | Recombinant Proteins - immunology | Aluminum Hydroxide - immunology | Studies | Immunology | Lymphocytes | Rodents | Clinical trials | Diabetes | Autoimmune diseases | Molecular weight | Diabetes mellitus | Immunotherapy | Glutamate decarboxylase | Lymphocytes T | Vaccines | Pancreas | Immunological tolerance
Journal Article
Neuroscience, ISSN 0306-4522, 2015, Volume 303, pp. 586 - 594
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2012, Volume 7, Issue 3, p. e33548
Background/Aim: Second generation antipsychotics (SGAs) are used to treat schizophrenia but can cause serious metabolic side-effects, such as obesity and... 
BODY-WEIGHT | RAT ARCUATE NUCLEUS | GLUTAMIC-ACID DECARBOXYLASE | MESSENGER-RNA EXPRESSION | FOOD-INTAKE | MULTIDISCIPLINARY SCIENCES | Y-LIKE IMMUNOREACTIVITY | DIET-INDUCED OBESITY | LONG-TERM TREATMENT | DORSAL VAGAL COMPLEX | NEUROPEPTIDE-Y | Gene Expression - drug effects | gamma-Aminobutyric Acid - metabolism | Antipsychotic Agents - adverse effects | Weight Gain - physiology | Neuropeptide Y - genetics | RNA, Messenger - metabolism | Neuropeptide Y - metabolism | Arcuate Nucleus of Hypothalamus - drug effects | Base Sequence | Female | Synaptic Transmission - drug effects | Weight Gain - drug effects | Intra-Abdominal Fat - drug effects | Pro-Opiomelanocortin - genetics | Cannabinoids - metabolism | Arcuate Nucleus of Hypothalamus - metabolism | RNA, Messenger - genetics | Appetite Regulation - drug effects | Rats | Glutamate Decarboxylase - genetics | Rats, Sprague-Dawley | Pro-Opiomelanocortin - metabolism | Eating - drug effects | Receptor, Cannabinoid, CB1 - metabolism | Animals | Models, Biological | Glutamate Decarboxylase - metabolism | Benzodiazepines - adverse effects | Appetite Regulation - physiology | Neuropeptide Y | Obesity | Olanzapine | RNA | Body weight | GABA | Schizophrenia | Glutamate decarboxylase | Intermedin | Glutamate | Glutamic acid | Brain | Health sciences | Neurosciences | Neuroleptics | Adipose tissue | Transcription | Mental disorders | Brain stem | Arcuate nucleus | Fuel consumption | Proopiomelanocortin | Biochemistry | Hypothalamus | Psychotropic drugs | γ-Aminobutyric acid | Alterations | Energy | Rodents | Vagus nerve | Drug dosages | Food | Binding | Neurochemistry | Appetite | Diabetes mellitus | Radioactive half-life | Cannabinoid CB1 receptors | Metabolism | Gene expression | Studies | Side effects | Brain research | Liability | Weight reduction | Receptor density | Ligands | Neurotransmission
Journal Article